Hepatitis C and insulin action: An intimate relationship

Jan 18 2016 Abstract Chronic hepatitis C virus (HCV) infection has been shown to be linked to a higher prevalence of type 2 diabetes compared with the general population or with patients with chronic hepatitis B infection and diabetes is the most common extra-hepatic manifestation of HCV. The HCV-diabetes association…

Read More

Painful Liver Biopsies May Be a Thing of the Past

January 15, 2016 Advancements in technology — especially in the field of medicine — can be life changing. For someone suffering from a severe medical condition, even the slightest advancement can provide a world of difference. Recently, a new type of imaging technology called elastography is helping hepatitis patients in…

Read More

New Virus Has Strong Association With Hepatitis C

New Human Virus Linked With Hepatitis C December 22, 2015 Each year, millions of people across the globe depend on life-saving blood transfusions. Needless to say, ensuring this limited supply is clean is imperative to ensure the safety of vulnerable recipients. This message has just been highlighted by a new…

Read More

Hep C Drugs in 2016: More Combos and Lower Cost

January 11, 2016 Hepatitis C treatment has improved dramatically in the past few years. More than ever before, eliminating the Hepatitis C virus from the bloodstream is now accompanied by favorable odds. Efforts to eradicate this virus have been steadily gaining momentum, as the pharmaceutical industry has made Hepatitis C…

Read More

Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages

Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with a dismal prognosis for most patients. Fibrosis and inflammation are hallmarks of tumor desmoplasia. We have previously demonstrated that preventing the activation of pancreatic stellate cells (PSCs) and alleviating desmoplasia are beneficial strategies in treating PDAC. Metformin is a widely…

Read More

Antiviral potential found in hepatitis C virus

6 January 2016 In a study published in the Biophysical Journal, the team shows how the molecule – called AH peptide – could have a powerful antiviral effect against viruses that have cholesterol-rich membranes, such as West Nile, dengue, measles,and human immunodeficiency virus (HIV). The researchers believe their findings could…

Read More

AbbVie Seeks OK for Ribavirin-Free Viekira Pak for Hep C 1b

January 13, 2016 The U.S. Food and Drug Administration (FDA) has granted priority review to AbbVie’s supplemental new drug application for a new indication for Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir): to treat those with genotype 1b of the virus and compensated cirrhosis without ribavirin. The current dosing recommendation for this group…

Read More

FDA Grants Priority Review to New Gilead Hep C Combo Tablet

January 11, 2016 The U.S. Food and Drug Administration (FDA) has granted priority review status to Gilead Sciences’ investigational pangenotypic hepatitis C virus (HCV) fixed-dose combination tablet, which includes Sovaldi (sofosbuvir) and velpatasvir. The designation secures a target decision date of June 28. Gilead applied for approval of Sovaldi/velpatasvir on…

Read More